Results 161 to 170 of about 180,642 (297)

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Reply: The Persistent Burden of Rheumatic Heart Disease in Africa. [PDF]

JACC Asia
Chan VH, So KC.
europepmc   +1 more source

RHEUMATISM AND HEART DISEASE

American Journal of Public Health and the Nations Health, 1928
openaire   +3 more sources

Sequential catalytic nanosystem of carbon dots and uricase integrated with polydopamine for therapy of gouty wound ulceration

BMEMat, EarlyView.
Sequential dual‐catalytic treatment of the gout wound ulceration process by CDs‐Uri@PDA. (a) Synthesis steps and morphology of CDs‐Uri@PDA. (b) Sequential treatment process and mechanism of CDs‐Uri@PDA for gout wound ulceration according to (i) uric acid reduction, (ii) antibacterial activity, and (iii) anti‐inflammatory effects.
Yonglan Yang, Yang Yang, Pengpeng Ma, Ruiqi Zhu, Xia Pan, Shaoling Zheng, Bo Chen, Yanli Jin, Youcong Gong, Jie Liu, Tianwang Li, Xu Chen   +11 more
wiley   +1 more source

Prevalence-incidence bias in longitudinal studies of rheumatic heart disease in Fiji. [PDF]

BMC Cardiovasc Disord
Cua T, Talukder S, Perman ML, Engelman D, Steer A, Kado J, Parks T.   +6 more
europepmc   +2 more sources

Intraosseous sarcoidosis imitating peri‐implantitis: A case study

Clinical Advances in Periodontics, EarlyView.
Abstract Background Sarcoidosis is a multisystem granulomatous disorder of unknown cause, typically affecting the lungs and lymph nodes, but it can also involve the eyes, skin, heart, bones, and other organs. The exact cause is unclear, but genetic factors and environmental triggers like infections, chemicals, or dust may play a role.
Magdalena Orlowska, David S. Gottlieb, Kenneth S. Kornman   +2 more
wiley   +1 more source

Evaluation of a training program for rheumatic heart disease screening integrated into the public health system in Uganda. [PDF]

PLoS One
Warren PW, Wirth S, Pulle J, Nakaagayi D, Akia CO, Ayaa E, Pardo M, Odong F, Ogwanh R, Omagino J, Otim I, Sable C, Spaziani A, Otto HO, Watkins D, Okello E, Danforth K, Beaton A.   +17 more
europepmc   +1 more source

The Epidemiological Landscape and Burden of Chronic Disease in Australia: Contextualizing the Distinct Profile of Tasmania

Chronic Diseases and Translational Medicine, EarlyView.
ABSTRACT Chronic diseases are the leading causes of morbidity and mortality worldwide and impose a substantial and long‐lasting burden on individuals, families, communities, and healthcare systems. In Australia, more than 47% of the population had at least one chronic condition in 2018, and the prevalence rose sharply with age: approximately 80% of ...
Getahun Kebede Beyera
wiley   +1 more source

Opioid Toxicity Following Concomitant Use of Macrolide Antibiotics with Fentanyl, Hydromorphone, or Oxycodone: A Population‐Based Study

Clinical Pharmacology &Therapeutics, EarlyView.
Fentanyl, hydromorphone, and oxycodone are metabolized by cytochrome P450 3A4 (CYP3A4). Co‐administration with CYP3A4‐inhibiting macrolides (clarithromycin or erythromycin) may increase opioid concentrations and overdose risk, but the clinical impact of these interactions is unknown.
Tony Antoniou, Joanna Yang, David N. Juurlink, Joanne M.‐W. Ho, Muhammad Mamdani, Fangyun Wu, Mina Tadrous, Tara Gomes   +7 more
wiley   +1 more source

The impact of heart valve replacement surgery start time on patients with rheumatic heart disease. [PDF]

Front Cardiovasc Med
Wang C, Zhang S, Li M, Zhang W.
europepmc   +1 more source